AAA CEUS: Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair

Sponsor
E. Peden, MD (Other)
Overall Status
Completed
CT.gov ID
NCT01005212
Collaborator
Lantheus Medical Imaging (Industry), The Methodist Hospital Research Institute (Other)
40
2
32
20
0.6

Study Details

Study Description

Brief Summary

This study will be a cross-sectional survey of interobserver variability associated with contrast enhanced ultrasound (CEUS) to detect endoleaks using computed tomographic angiography (CTA) as the practice standard. The investigators will enroll 40 consecutive patients undergoing endovascular abdominal aortic aneurysm repair (EVAR). At the first follow-up visit after the procedure, participants will undergo two abdominal ultrasound examinations with and without contrast, and one CTA. Analyses will be conducted to examine interobserver variability in the detection and characterization of endoleaks using contrast-enhanced ultrasound (CEUS). Other endpoints include examination of sensitivity and specificity of CEUS compared to CTA, and characterization of the number and types of endoleaks detected.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Actual Enrollment :
40 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair
Study Start Date :
Jan 1, 2008
Actual Primary Completion Date :
Sep 1, 2010
Actual Study Completion Date :
Sep 1, 2010

Outcome Measures

Primary Outcome Measures

  1. To examine the sensitivity and specificity of CEUS compared to CTA Hypothesis [30 Days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 18 years of age or greater;

  2. Diagnosed with abdominal aortic aneurysm and has undergone or is scheduled to undergo endovascular repair procedure.

  3. Has not completed the first scheduled post-treatment follow-up exam

  4. Voluntary participation and signature of IRB-approved informed consent.

Exclusion Criteria:
  1. Inability to consent (includes non-English speaking patients)

  2. Has already completed the first scheduled post-treatment follow-up exam.

  3. Clinical instability;

  4. Pregnancy / breast feeding;

  5. Known allergy to perflutren;

  6. Known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts (based on manufacturer recommendations for use);

  7. Recent heart attack (<6 months), unstable angina or uncontrolled cardiopulmonary disease

  8. Clinically unstable or recent worsening congestive heart failure (based on FDA warning)

  9. Serious ventricular arrhythmias or at high risk for arrhythmias

  10. Respiratory failure (based on FDA warning)

  11. Severe emphysema, pulmonary emboli or other conditions that compromise pulmonary arterial vasculature (based on FDA warning)

  12. Any reason judged by the investigators to hamper inclusion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Houston Methodist Hospital; Department of Cardiovascualr Surgery Houston Texas United States 77030
2 Houston Methodist Hospital; Department of Cardiovascular Surgery Houston Texas United States 77030

Sponsors and Collaborators

  • E. Peden, MD
  • Lantheus Medical Imaging
  • The Methodist Hospital Research Institute

Investigators

  • Principal Investigator: Eric Peden, MD, Houston Methodist Hosptial

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
E. Peden, MD, Sponsor-Investigator/Principal Investigator, The Methodist Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT01005212
Other Study ID Numbers:
  • Pro00001211
  • 1007-0202
First Posted:
Oct 30, 2009
Last Update Posted:
Oct 2, 2017
Last Verified:
Sep 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by E. Peden, MD, Sponsor-Investigator/Principal Investigator, The Methodist Hospital Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 2, 2017